Form 4: Jaguar Health Director Acquires Convertible Note and Warrants

Director Jonathan B. Siegel acquired a convertible promissory note and warrants in Jaguar Health, Inc.

Summary

• On March 31, 2025, Jonathan B. Siegel, a director of Jaguar Health, Inc., acquired a 6% convertible promissory note and a warrant to purchase common stock.
• The convertible note, with a face value of $50,000, is convertible into 9,000 shares of common stock at a price of $5.555 per share.
• The note matures three months after issuance.
• The warrant allows Siegel to purchase up to 9,000 shares of common stock at an exercise price of $5.43 per share.
• The warrant is exercisable immediately and expires five years from the date of issuance, upon a fundamental transaction, or upon a liquidation event.
• Siegel also indirectly owns 9,000 shares of common stock through JBS Healthcare Ventures LLC, where he is the sole member.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing simply reports a transaction. The director's investment could be seen as a positive, but it's a standard disclosure.

Positives

• The investment by a director could be seen as a positive signal about the company's prospects.

Risks

• The convertible note could lead to dilution of existing shareholders if converted into common stock.
• The exercise of the warrants could also lead to dilution.

Future Outlook

The document does not contain specific forward-looking statements beyond the terms of the convertible note and warrant.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency into their transactions in the company's securities. This particular filing indicates a director's investment in the company, which can be viewed in the context of overall investor sentiment and company performance.

Comparison to Industry Standards

• Convertible notes and warrants are common financing tools used by companies, particularly smaller ones, to raise capital.
• The terms of the note and warrant (interest rate, conversion price, exercise price, and expiration date) would need to be compared to similar transactions in the biotechnology industry to assess their favorability.
• Comparable companies in the biotechnology sector often use similar instruments to fund research and development activities.

Stakeholder Impact

• Shareholders may be impacted by potential dilution if the convertible note is converted and the warrants are exercised.
• The investment by a director could be viewed positively by the market.

Key Dates

Keywords

Jaguar Health, Convertible Note, Warrant, Director, Jonathan B. Siegel, JAGX, Beneficial Ownership